A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome (NMS), a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years.
Mary Ann Liebert, Inc.Sep 19 2024 A new study in the peer-reviewed Journal of Child and Adolescent Psychopharmacology estimated the incidence of neuroleptic malignant syndrome , a potentially fatal adverse effect of antipsychotic treatment, among individuals ages 5-24 years.
"Patients with 4 or 5 of these factors had more than 100 times the incidence of those with none," reported the investigators.
Children Malignant Neuroleptic Malignant Syndrome Syndrome Medicine Psychopharmacology Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Understanding the risks for young mothers in child care proceedingsMothers under the age of 20 are at the greatest risk of being involved in care proceedings in the 10 years after having their first child, finds a new study report led by UCL researchers.
Read more »
How to pick the best preschool or child care center for your childPreschool options are growing as states expand early learning programs. That means parents face a dizzying array of choices.
Read more »
How to pick the best preschool or child care center for your childPreschool options are growing as states expand early learning programs. That means parents face a dizzying array of choices.
Read more »
Parents could be due over £209 in monthly payments before end of this yearScottish Child Payment, Child Benefit and Best Start Grants can provide crucial financial support for families.
Read more »
Child, 2, 'picked up from pram in attempted kidnap' at busy storeHe allegedly turned to the child's mother saying he will 'take the child'.
Read more »
Understanding Changes in Pre-Clinical Alzheimer's Disease: Study Finds Two Proteins Impact Brain Activity DifferentlyA new study has shed light on the role of two proteins, amyloid beta and tau, in pre-clinical Alzheimer's disease. Researchers found that these proteins impact brain activity differently, potentially offering new insights into the progression of the disease.
Read more »